LYT-100 (deuterated pirfenidone) is designed to retain the beneficial pharmacology and clinically validated efficacy of pirfenidone, but with a highly differentiated PK profile that has translated into substantially improved tolerability in multiple clinical trials. We believe improved tolerability could unlock better outcomes for patients through increased medication adherence and potentially improved efficacy at a higher dose.
SPT-300 was invented at PureTech. Allopregnanolone has the potential to treat a range of neurological and neuropsychiatric indications, however it can only be administered via a long, cumbersome intravenous infusion. Oral chemical analogs have been developed but they may have different pharmacological effects than endogenous allopregnanolone. With SPT-300, we have achieved oral bioavailability approximately nine times greater than third party reported data with oral allopregnanolone, which significantly expands the potential of this validated mechanism.
For patients with a range of mental health conditions, such as anxiety and mood disorders, there is a growing need for new treatments. Standard of care treatments like selective serotonin reuptake inhibitors (SSRIs) can have mixed efficacy, delayed onset of action and poor tolerability.
Lower levels of allopregnanolone have been documented in patients with mood disorders, such as depression, and there is evidence that allopregnanolone has therapeutic potential in both anxiety and depression, however it can only be administered via a long, cumbersome intravenous infusion.
We created an oral prodrug of endogenous allopregnanolone that retains the activity and potency of allopregnanolone and may have better target engagement, in a more convenient oral form. We’ve done so by linking it to our Glyph™ technology, which allows it to bypass liver degradation. With this approach, we have demonstrated oral bioavailability that is approximately nine times greater than that of previous efforts to develop oral allopregnanolone. This means SPT-300 may significantly expand the potential of this validated mechanism across multiple patient populations where current treatments are burdensome to administer or take weeks to have an effect.